Drug Trial Radar · NCT07707895
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Nov 3, 2026
Primary completion
Apr 26, 2030
Study completion Apr 26, 2030
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- Collaborators
- Zai Lab
- First posted
- Jul 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with advanced small cell lung cancer and other neuroendocrine cancers. The study has 2 parts. The purpose of Part 1 is to find a suitable dose of a combination study treatment, obrixtamig and ZL-1310. The purpose of Part 2 is to see how obrixtamig and ZL-1310 is tolerated when given with another medicine called a checkpoint inhibitor. Another purpose is to check whether the study treatment can stop the cancer from growing and keep it stable. Obrixtamig and ZL-1310 are being developed to help the immune system fight cancer. In Part 1, participants get obrixtamig and ZL-1310. In Part 2, participants get obrixtamig and ZL-1310 with a checkpoint inhibitor. Part 2 is only open to people with advanced small cell lung cancer. All study treatments are given as infusions into a vein. The study does not have a fixed duration. Participants can receive study treatment for up to 2 years if they benefit from treatment and can tolerate it. Participants visit the study site regularly, with some overnight stays required. During this time, doctors regularly check for health problems that could be caused by the study treatment. They also monitor the size of the tumour(s) and take laboratory tests.
Conditions
- Small Cell Lung Cancer
- Large Cell Neuroendocrine Lung Carcinoma
- Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
- Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
Interventions
ObrixtamigDrug
Obrixtamig
ZL-1310Drug
ZL-1310
AtezolizumabDrug
Atezolizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: The occurrence of dose limiting toxicities (DLTs) during the DLT evaluation periodTime frame: 6 weeks from the first administration of study medication.
- Part 2: The occurrence of treatment-emergent adverse events (AEs) leading to trial medication discontinuation or dose modificationTime frame: Up to 24 months.
- Part 2: PFS rate at 6 monthsTime frame: At 6 months.
Locations
28 sites in 11 countries. Site status is shown where the registry gives one.
MedStar Georgetown University Hospital
Washington D.C., District of Columbia · Not yet recruiting
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida · Not yet recruiting
University of Kentucky Medical Center
Lexington, Kentucky · Recruiting
Chris Obrien Lifehouse
Camperdown, New South Wales, Australia · Not yet recruiting
Royal North Shore Hospital
St Leonards, New South Wales, Australia · Not yet recruiting
Universitair Ziekenhuis Antwerpen
Edegem, Belgium · Not yet recruiting
Universitair Ziekenhuis Gent
Ghent, Belgium · Not yet recruiting
The Affiliated Cancer Hospital, Guangxi Medical University
Nanning, China · Not yet recruiting
Shanghai Chest Hospital
Shanghai, China · Not yet recruiting
Shanghai Pulmonary Hospital
Shanghai, China · Not yet recruiting
CTR Leon Berard
Lyon, France · Not yet recruiting
HOP Timone
Marseille, France · Not yet recruiting
Institut Gustave Roussy
Villejuif, France · Not yet recruiting
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Germany · Not yet recruiting
Robert Bosch Gesellschaft für medizinische Forschung mbH
Stuttgart, Germany · Recruiting
Hokkaido Cancer Center
Hokkaido, Sapporo, Japan · Not yet recruiting
St. Marianna University Hospital
Kanagawa, Kawasaki, Japan · Not yet recruiting
Kansai Medical University Hospital
Osaka, Hirakata, Japan · Not yet recruiting
Shizuoka Cancer Center
Shizuoka, Sunto-gun, Japan · Not yet recruiting
Amsterdam UMC Locatie VUMC
Amsterdam, Netherlands · Not yet recruiting
Szpital Specjalistyczny W Brzozowie Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza
Brzozów, Poland · Not yet recruiting
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Warsaw, Poland · Not yet recruiting
Lower Silesian Oncology Centre
Wroclaw, Poland · Not yet recruiting
Hospital Duran i Reynals
L'Hospitalet Del Llobregat, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Clinico De Valencia (INCLIVA)
Valencia, Spain · Recruiting
Leicester Royal Infirmary
Leicester, United Kingdom · Not yet recruiting
Freeman Hospital
Newcastle upon Tyne, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.